Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

Speciality: Oncology

Description:

A warm welcome to all the medical professionals joining this insightful session on the role of pazopanib in managing renal cell carcinoma (RCC).

Kidney cancer, or renal cancer, is among the most common malignancies affecting both men and women. Alarmingly, its global incidence and burden continue to rise with time. Advanced RCC, categorized as stage 4 kidney cancer, is particularly aggressive and often proves difficult to cure, requiring a multifaceted treatment approach.

In most clinical scenarios, healthcare professionals focus on slowing disease progression, managing symptoms, and improving the quality of life for patients. Fortunately, ongoing research in advanced RCC has led to the development and FDA approval of novel therapies with better outcomes.

Pazopanib is a targeted oral anti-cancer medication that inhibits tumor growth through multiple mechanisms. It acts on a range of proteins, especially tyrosine kinases, present on the surface of cancer cells. Additionally, many of these proteins are involved in angiogenesis, the process of forming new blood vessels that supply nutrients and oxygen to tumors, supporting their growth.

This session will provide a comprehensive overview of pazopanib's role in treatment strategies, its mechanism of action, clinical applications, and evidence-based outcomes. So, stay engaged, absorb the valuable insights, and be sure to follow HiDoc for more such informative and impactful webinar sessions.

See More Webinars @ Hidoc Webinars